Shares of Johnson & Johnson (NYSE:JNJ) have received a consensus recommendation of “Hold” from the twenty-two ratings firms that are covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $145.64.

A number of equities research analysts have issued reports on JNJ shares. Citigroup started coverage on shares of Johnson & Johnson in a research note on Monday, September 25th. They set a “neutral” rating and a $140.00 price objective on the stock. Zacks Investment Research cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a report on Wednesday, September 27th. UBS Group reissued a “buy” rating and issued a $148.00 target price on shares of Johnson & Johnson in a report on Saturday, September 30th. Piper Jaffray Companies reissued a “hold” rating and issued a $120.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 4th. Finally, Cowen set a $147.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Friday, October 6th.

Shares of Johnson & Johnson (NYSE JNJ) opened at $147.36 on Friday. The stock has a market cap of $395,890.00, a PE ratio of 25.58, a price-to-earnings-growth ratio of 2.75 and a beta of 0.80. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a one year low of $110.76 and a one year high of $148.32.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. The firm had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a net margin of 19.16% and a return on equity of 20.70%. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the prior year, the company posted $1.68 earnings per share. equities analysts predict that Johnson & Johnson will post 7.28 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be issued a $0.84 dividend. The ex-dividend date is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a yield of 2.28%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in Johnson & Johnson by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after buying an additional 3,023,110 shares during the last quarter. BlackRock Inc. raised its holdings in Johnson & Johnson by 2.6% in the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after buying an additional 4,332,612 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Johnson & Johnson by 0.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock valued at $4,757,593,000 after buying an additional 130,437 shares during the last quarter. FMR LLC raised its holdings in Johnson & Johnson by 5.9% in the 2nd quarter. FMR LLC now owns 27,237,648 shares of the company’s stock valued at $3,603,268,000 after buying an additional 1,509,745 shares during the last quarter. Finally, Capital World Investors increased its position in Johnson & Johnson by 4.1% during the 2nd quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock valued at $3,507,009,000 after purchasing an additional 1,050,000 shares during the period. Institutional investors and hedge funds own 65.71% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2018/01/20/johnson-johnson-jnj-given-consensus-recommendation-of-hold-by-analysts.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.